







Impact of a Community Health Workers-Led Structured Program on Blood Glucose Control Among Latinos With Type 2 Diabetes: The DIALBEST Trial

Diabetes Care 2015;38:197-205 | DOI: 10.2337/dc14-0327

Rafael Pérez-Escamilla, 1,2 Grace Damio,3 Jyoti Chhabra,⁴ Maria L. Fernandez,² Sofia Segura-Pérez, Sonia Vega-López, 5 Grace Kollannor-Samuel, Mariana Calle, 6 Fatma M. Shebl, and Darrin D'Agostino

OBJECTIVE

Latinos with type 2 diabetes (T2D) face major healthcare access and disease management disparities. We examined the impact of the Diabetes Among Latinos Best Practices Trial (DIALBEST), a community health worker (CHW)-led structured intervention for improving glycemic control among Latinos with T2D.

RESEARCH DESIGN AND METHODS

A total of 211 adult Latinos with poorly controlled T2D were randomly assigned to a standard of healthcare (n = 106) or CHW (n = 105) group. The CHW intervention comprised 17 individual sessions delivered at home by CHWs over a 12-month period. Sessions addressed T2D complications, healthy lifestyles, nutrition, healthy food choices and diet for diabetes, blood glucose self-monitoring, and medication adherence. Demographic, socioeconomic, lifestyle, anthropometric, and biomarker (HbA_{1c}, fasting blood glucose, and lipid profile) data were collected at baseline and 3, 6, 12, and 18 months (6 months postintervention). Groups were equivalent at baseline.

RESULTS

Participants had high HbA_{1c} at baseline (mean 9.58% [81.2 mmol/mol]). Relative to participants in the control group, CHWs had a positive impact on net HbA1c improvements at 3 months (-0.42% [-4.62 mmol/mol]), 6 months (-0.47% mmol/mol)[-5.10 mmol/mol]), 12 months (-0.57% [-6.18 mmol/mol]), and 18 months (-0.55% [-6.01 mmol/mol]). The overall repeated-measures group effect was statistically significant (mean difference -0.51% [-5.57 mmol/mol], 95% CI -0.83, -0.19% [-9.11, -2.03 mmol/mol], P = 0.002). CHWs had an overall significant effect on fasting glucose concentration that was more pronounced at the 12- and 18-month visits. There was no significant effect on blood lipid levels, hypertension, and weight.

DIALBEST is an effective intervention for improving blood glucose control among Latinos with T2D.

See accompanying articles, pp. 186, 189, 206, 213, 220, and 228.

¹Yale School of Public Health, New Haven, CT ²University of Connecticut, Storrs, CT

³Hispanic Health Council, Hartford, CT

⁴Hartford Hospital, Hartford, CT

⁵Arizona State University, Phoenix, AZ

⁶Worcester State University, Worcester, MA

⁷University of North Texas, Denton, TX

Corresponding author: Rafael Pérez-Escamilla, rafael.perez-escamilla@yale.edu.

Received 3 February 2014 and accepted 16 July 2014.

Clinical trial reg. no. NCT01299844, clinicaltrials

This article contains Supplementary Data online at http://care.diabetesiournals.org/lookup/ suppl/doi:10.2337/dc14-0327/-/DC1.

^{© 2015} by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Latinos, the fastest growing minority group in the U.S. (1), suffer from a disproportionate burden of type 2 diabetes (T2D) (2) and related complications (3,4). Tangible disparities exist among Latinos in socioeconomic status, health insurance coverage, and use and quality of healthcare services (5,6). Prevalence of obesity (37.9% vs. 33.9%) (7) and physical inactivity (8)—risk factors associated with poor diabetes control-are also more prevalent among Latinos.

Effective metabolic glycemic control has been consistently shown to reduce the incidence of diabetes-related complications in large clinical trials (9,10). Current T2D care guidelines emphasize healthy lifestyles and behavioral change, such as eating a healthy diet, getting regular physical activity, attending primary and specialty clinic visits, and monitoring glycemic control (11). Traditional treatment strategies that focus on medication alone are not enough to achieve diabetes goals among Latinos (12). Limited English proficiency often leads to communication barriers between healthcare providers and Latino patients (13). Lack of provider crosscultural communication skills to address cultural values among Latinos might result in patient dissatisfaction, treatment noncompliance, and delay in seeking medical help (14). Medical education and support delivered in a community setting by well-trained and supervised local, bilingual community health workers (CHWs) who understand the community's social determinants of health are likely to improve T2D care among Latinos (15,16).

Only a handful of randomized controlled trials (RCTs) have tested the effectiveness of diabetes education programs delivered by CHWs (17-26). Collectively, these studies demonstrated significant improvements in healthy lifestyle behaviors, diabetes knowledge, and HbA_{1c} levels. Most intervention strategies have been group based (17,19-25), clinic based (18), or telephone based (20,25) rather than home based (26). In the only homebased intervention study (26), CHWs were not integrated as part of the healthcare management team, and the sustainability of impact on glycemic control postintervention was not assessed. Thus, the objective of the present community-based RCT was to evaluate whether home-based, culturally appropriate counseling delivered by CHWs integrated as part of the healthcare management team can improve glycemic control among Latino adults with T2D and whether the impact is sustained after the intervention ends.

RESEARCH DESIGN AND METHODS

Study Design

The Diabetes Among Latinos Best Practices Trial (DIALBEST) was a parallel, community-based RCT. DIALBEST targeted Latino adults with T2D who attended a community-based ambulatory primary care clinic. Baseline screening was conducted using an electronic medical record database to identify eligible candidates who were contacted in person by recruiters on their clinical appointment day at the primary care clinic. Patients were eligible to participate if they 1) were aged \geq 21 years; 2) had a documented diagnosis of T2D for >12 months; 3) lived in Hartford County, CT; 4) had HbA_{1c} levels \geq 7% (53 mmol/mol); and 5) self-identified as Hispanic/ Latino. Exclusion criteria were 1) pregnancy or breastfeeding; 2) renal failure; 3) active cancer; 4) active hepatitis or advanced cirrhosis; 5) end-stage liver disease; 6) cognitive impairment, dementia, or Alzheimer disease; 7) active and severe mental health problems; 8) a cardiovascular disease event in the previous 12 months (assessed by a physician at the clinic); 9) medical conditions that completely limit ability to perform physical activity independently (e.g., limb amputation, permanent physical disability, blindness); and 10) inability to consume meals orally. Written informed consent and contact information were collected at the clinic.

A total of 211 participants were enrolled from December 2006 to February 2009 and were randomly assigned into either the standard of care (n = 106) or standard of care plus a 12-month-long, CHW-led, culturally tailored diabetes education and counseling treatment group (n = 105). Block randomization involving randomly selected block sizes of four was implemented through computergenerated binary random group assignment. The CHWs visited the treatment group participants at home weekly during the first month, biweekly during months 2 and 3, and monthly thereafter until month 12. Data collection took

place at baseline and 3, 6, and 12 months postenrollment to assess the intervention phase and then 6 months thereafter to assess the intervention maintenance phase. Overall, the 18-month attrition rate was 29.9% (34.9% in the control group vs. 24.8% in the intervention group, P = 0.107) (Fig. 1).

Standard of Care

At the time of the study, clinic providers were trained based on American Diabetes Association guidelines and the practice guidelines developed for the clinics. Goals for care, metrics for success, and quality outcomes were monitored to ensure compliance with these guidelines. Every physician (resident or attending) was trained to check HbA_{1c} levels every 3 months and to conduct yearly foot, urine, and eye examinations. The standard practice in the clinic was to measure height, weight, and blood pressure at each visit. Five attending physicians served as mentors to ~42-48 residents per year equally split across 3 years of residency. The resident physicians were considered as the primary providers and, thus, were responsible for scheduled appointments and routine medical follow-ups. Patients needing urgent evaluation or intervention were able to access the same clinic system but often had to be seen by a different physician for acute care. All patients with T2D were given a glucometer and prescription for glucose test strips and were educated on their proper use. Patients were referred to a clinic dietitian if during a medical visit the healthcare provider discovered major nutritionrelated issues. Patients were allowed to purchase their prescriptions at a hospital-based pharmacy at greatly discounted costs. In the last year of this program, the dispensing of discounted medications was discontinued, but study participants received their medications free of cost from the hospital for the duration of their enrollment so as not to adversely affect the study design. This study was approved by the institutional review boards of the University of Connecticut, Hartford Hospital, and the Hispanic Health Council.

CHW DIALBEST Intervention Curriculum

The DIALBEST curriculum was built upon extensive community-based participatory research work in the target community (27,28) and was designed to provide




Figure 1—Study design flowchart. f/up, follow-up.

culturally and health literacy appropriate counseling, including informational and instrumental education, skills, and support in the areas of nutrition and food access, physical activity, blood glucose monitoring, medication adherence, and compliance with medical appointments. The DIALBEST curriculum was organized into 17 home-visit sessions delivered by two well-trained and supervised bilingual/bicultural CHWs. Each participant in the intervention group was randomly assigned to and only seen by one of the CHWs. The CHW delivered a comprehensive set of well-structured curriculum modules that exceeded the American Diabetes Association medical nutrition therapy standards (29). The modules focused on T2D and its complications, nutrition, physical activity, blood glucose selfmonitoring, adherence to medications and medical appointments, and mental health (Supplementary Table 1). Each module included educational materials with graphics to illustrate key concepts and hands-on activities to improve instrumental knowledge for T2D selfmanagement (e.g., onsite supermarket education on comparative shopping guided by food label reading).

DIALBEST was patient centered and grounded in principles of behavioral change theory, including stages of change, problem-solving theory, and motivational interviewing. As recommended (29,30), the intervention was individually

tailored, taking heavily into account the language preference and specific socioeconomic circumstances of each participant. At each visit, the CHW and patient jointly developed a T2D self-management plan based on the individual patient's clinical history and previous challenges experienced with T2D self-management. Further individual tailoring was determined based on the patient's stage of change, level of motivation, health literacy, and social support. Home visits were scheduled only during weekdays. If endorsed by the patient, family members present at home during home sessions were allowed to participate.

CHW Training

The two DIALBEST bilingual/bicultural CHWs, a nurse trained in Puerto Rico and a medical assistant originally from El Salvador, underwent 65 h of core training that included T2D pathophysiology and risk factors, lifestyle strategies for glycemic control (nutrition, physical activity, prevention of diabetes complications, and diabetes care), glucose selfmonitoring, and T2D medications. More than 25 h of supplemental training were provided, including program delivery topics on motivational interviewing and communication skills (Supplementary Table 2) and topics related to social determinants of health and cultural competence. The trainings were delivered by an interdisciplinary team of academics and practitioners with expertise in clinical medicine, health inequities,

Latino health, diabetes self-management, diabetes medications, nutrition, exercise, cross-cultural counseling, and mental health.

CHW Integration Into Healthcare Management Team

The CHWs were employed at a communitybased nonprofit organization. They attended weekly meetings with the field supervisor as well as with the health management coordination team at the clinic, which included the primary care clinic medical team and the clinic's dietitian. At these meetings, the CHWs informed the healthcare professionals of any serious barriers and challenges and T2D management issues faced by participants in the intervention group. Medical providers explained various treatment and management options that might work better with those patients unable to self-manage their T2D. This helped to coordinate the feedback of the CHWs with the care given. Feedback was delivered to the individual providers by the clinic director, who was also the study's medical director, along with education indicating why management change was suggested. Recommended management changes included adjustments in medication type or dose, timing for eating, timing for taking medication, and adding a snack in the diet before bed (to manage nocturnal hypoglycemia) as well as the type of bedtime snack (high in protein to prevent hyperglycemia at night). Thus, one of the key goals of DIALBEST was to improve the continuum of care of highly impoverished patients with T2D following the Chronic Care Model framework (31).

Data Collection

Data were collected at each participant's home at baseline and 3, 6, 12, and 18 months by one of five community bilingual interviewers not involved with the healthcare team and blinded to the care delivery group. At baseline, a battery of questions captured socioeconomic; demographic; acculturation; social support; T2D self-management knowledge, attitudes, and behaviors (diet, physical activity, blood glucose self-monitoring, and medication use); and mental health information (32-34). Findings of the impact of the intervention on T2D self-management will be reported elsewhere.

A blood collection home visit was conducted for each participant after a 12-h overnight fast by a DIALBEST phlebotomist blinded to study group allocation. HbA_{1c} levels were measured in the home using the A1cNow InView pointof-care device (Metrika Inc., Sunnyvale, CA) from fasting capillary blood. Venous blood (20 mL) was collected into evacuated tubes coated with EDTA and EDTA/ sodium fluoride for the measurement of plasma glucose and lipid concentrations (triglycerides and total, HDL, and LDL cholesterol). Blood samples were transported to the laboratory, centrifuged at 2,200g for 30 min at 4°C to separate plasma, and stored at -70°C until analyzed by trained laboratory assistants blinded to group assignment. All biomarkers were measured in duplicate. Body weight (kg), height, waist and hip circumferences (cm), and blood pressure (assessed using a portable sphygmomanometer) were measured by trained interviewers in triplicate following recommended procedures.

A process evaluation ancillary study was conducted in the sample of participants who completed the intervention (n = 76). A research staff member not involved with the delivery of the intervention or prior data collection reviewed the CHWs' home visit intake forms and progress notes and phone call logs. He also reviewed changes in T2D self-management knowledge assessed by the CHWs during the home visits following a pre/posttest and interviewed the intervention completers to assess their satisfaction with DIALBEST (Supplementary Data) (35-38).

Data Analyses

We used SAS for Windows version 9.3 (SAS Institute Inc., Cary, NC) to impute missing values in all the analyses. We used multiple imputation methods to create five data sets with nonmissing values using the PROC MI procedure and then ran all the analyses on each data set followed by combining the estimates from multiple data sets to obtain a single estimate using the PROC MIANALYZE procedure. Fully conditional specification methods were used, with linear or logistic regression to impute continuous and binary variables, respectively (39), which achieved >90% relative efficiency. To assess baseline group balance, we conducted

between-group baseline comparisons for demographic, socioeconomic, blood glycemic and lipid levels, and anthropometric characteristics using the χ^2 test for categorical variables and independent samples ANOVA for continuous variables. Confounders of the primary and secondary outcomes were selected on the basis of the following criteria: 1) did not interact with intervention and 2) was significantly related to the outcome and intervention in the bivariate analysis. To assess the impact of the intervention on the primary outcome HbA_{1c} and to be able to compare and contrast the results to previously published studies, we modeled the HbA_{1c} outcome in three different ways: the measured raw HbA_{1c} values, HbA_{1c} reduction values, and HbA_{1c} percent change values. HbA_{1c} reduction at 3, 6, 12, and 18 months were defined as the HbA_{1c} values at 3, 6, 12, and 18 months minus the HbA_{1c} baseline value, respectively. HbA_{1c} percent change was calculated at 3, 6, 12, and 18 months as the HbA_{1c} reduction value divided by the HbA_{1c} baseline value. Subsequently, we followed two approaches. First, we conduct a linear mixed-effects (LME) repeated-measures analysis of HbA_{1c} raw values, HbA_{1c} reduction values, and HbA_{1c} percent change, adjusting for baseline HbA_{1c}, and included an interaction term that allowed us to estimate the net betweengroup HbA_{1c} difference across time points adjusted for confounders. The second approach was to conduct an LME repeated-measures analysis of postbaseline (i.e., excluding the baseline point from the model) HbA_{1c} raw values, HbA_{1c} reduction values, and HbA_{1c} percent change adjusted for time and confounders. We used the PROC MIXED procedure to conduct all LME modeling. LME models were also used to assess the secondary outcomes, including lipid profile, blood pressure, and weight. In all LME analyses of primary and secondary outcomes, we selected the best variance-covariance structure and final fixed- and randomeffects models using Akaike information criteria. The best model was the one with the smallest Akaike information criteria value. All analyses were conducted based on intention-to-treat principles, and values were imputed to replace missing data as indicated previously.

Attrition Bias Analysis

To assess attrition bias, we compared the baseline characteristics described previously between completers (n =148) and noncompleters (n = 63) at 18 months using χ^2 test for categorical variables and independent samples t test for continuous variables.

RESULTS

Sample Descriptive Characteristics

Study participants were, on average, 56 years old; 29% were married or living in common law; 26% had at least a high school education; 32% had a home computer, 22% Internet service at home, and 48% a car; 60% had a monthly income of \leq \$1,000, 84% were covered by Medicaid, 68.9% received supplemental security income, and 73% were enrolled in the Supplemental Nutrition Assistance Program. There were no significant between-group differences in any of the demographic and socioeconomic variables compared at baseline (Table 1).

At baseline, blood glycemic and lipid profiles were not different between groups, but mean systolic blood pressure was significantly higher in the intervention group yet within normal limits. Mean HbA_{1c} was 9.6% (81 mmol/mol), glucose 10.6 mmol/L, triglycerides 1.75 mmol/L, total cholesterol 4.65 mmol/L, LDL cholesterol 2.55 mmol/L, HDL cholesterol 1.33 mmol/L, and systolic blood pressure 118 mmHg. Likewise, there were no between-group differences in baseline anthropometry, including waist circumference (107.2 cm), weight (85.1 kg), height (1.58 m), and BMI (33.7 kg/m²) (Table 2).

DIALBEST Impact on HbA_{1c}

Results of the LME models that included time-by-intervention interaction and adjusted for baseline HbA_{1c} levels and age revealed that the DIALBEST intervention led to a net reduction HbA1c difference from baseline of -0.42% (-4.62mmol/mol) at 3 months (P = 0.043) followed by a net reduction difference of -0.47% (-5.10 mmol/mol) at 6 months (P = 0.050), -0.57% (-6.18 mmol/mol)at 12 months (P = 0.021), and -0.55%(-6.01 mmol/mol) at 18 months (P = 0.009) in favor of the CHW group (Table 3, Fig. 2). Consistent with these findings, the LME repeated-measures analyses that adjusted for baseline HbA_{1c} levels and age and were restricted to

Table 1—Demographic and socioeconomic characteristics among Connecticut Latinos with T2D participating in the DIALBEST trial

Variable	All (N = 211)	Control (n = 106)	CHW (n = 105)	P value
Age (years)	56.3 ± 11.8	57.3 ± 12.1	55.4 ± 11.5	0.245
Female sex	73.5	74.5	72.4	0.724
Language				0.439
English and Spanish	34.6	32.1	37.1	
Spanish	65.4	67.9	47.8	
Marital status				0.861
Single Married	28.0 22.3	29.2 22.6	26.7 21.9	
Common law	7.1	4.7	9.5	
Separated	10.9	11.3	9.5 10.5	
Divorced	17.1	17.0	17.1	
Widowed	14.7	15.1	14.3	
Highest school grade	2,	10.1	2.1.0	0.628
No schooling	4.3	3.8	4.8	0.028
≤8th grade	47.9	49.1	46.7	
Some high school	21.8	24.5	19.0	
High school/GED	17.1	15.1	19.0	
Technical	2.8	3.8	1.9	
Some college	5.2	2.8	7.6	
College	0.9	0.9	1.0	
Working	15.6	14.2	17.1	0.550
Possessions				
Telephone	77.3	82.1	72.4	0.093
Cell phone	64.5	67.0	61.9	0.441
Radio/CD player	77.7	77.4	78.1	0.898
Cable television	86.7	86.8	86.7	0.595
Video player	63.0	62.3	63.8	0.973
DVD player	69.0	71.7	66.3	0.402
Computer	32.2	31.1	33.3	0.732
Internet	22.3	20.8	23.8	0.713
Car	48.3	49.1	47.6	0.835
Microwave oven	93.8	94.3	93.3	0.748
Total monthly income				0.548
\$0–500	53.6	53.8	53.4	
\$501–1,000	25.4	24.5	26.2	
\$1,001–1,500	4.8	2.8	6.8	
\$1,501-2,000	2.4 7.2	3.8 8.5	1.0 5.8	
\$2,001–3,000 Unknown				
UTIKITOWIT	6.7	6.6	6.8	

Data are mean \pm SD or %. CD, compact disc; DVD, digital video disc; GED, General Educational Development.

postbaseline time points identified a significant overall group effect such that the intervention group had lower HbA_{1c} levels compared with the control group (mean difference -0.51% [-5.57 mmol/mol], 95% CI -0.83, -0.19% [-9.11, -2.03 mmol/mol], P=0.002). Similarly, the HbA_{1c} percent change was significantly higher in the CHW group compared with the control group (mean difference -5.52% [-7.33 mmol/mol], 95% CI -8.93, -2.11% [-11.9, -2.81 mmol/mol], P=0.002) (Table 3).

DIALBEST Impact on Secondary Outcomes

We also observed a significant effect of the intervention on fasting glucose. The CHW group had lower glucose concentrations compared with the control group (mean difference -1.08 mmol/L [95% CI -1.79, -0.39 mmol/L], P = 0.002) (Table 3). The intervention did not have a significant effect on HDL, LDL, and total cholesterol; triglycerides; systolic blood pressure; or weight (Table 3).

Attrition Bias Analysis

The overall dropout rate was 29.9% at 18 months, which was slightly lower among intervention than control participants (24.8% vs. 34.9%, respectively, P = 0.107). The majority of the noncompleters reported lack of time as a reason for dropping out (Fig. 1).

Completers and noncompleters were similar in baseline characteristics except that of 31 baseline comparisons, completers were more likely to have a cell phone (68.9% vs. 54%, P = 0.038) and were less likely to be married (18.2% vs. 31.7%, P = 0.013).

Process Evaluation

The positive impact of DIALBEST is well supported by the process evaluation conducted with study completers by a research assistant not involved with the trial. Specifically, the process evaluation based on CHW logs documented strong fidelity in the delivery of the intervention by CHWs, which in turn translated into improved T2D selfmanagement knowledge. Client satisfaction with DIALBEST was very high (35–38) (Supplementary Data).

CONCLUSIONS

DIALBEST Impact

To our knowledge, this RCT is the first to document the strong impact a homebased model can have on improving glycemic control among highly impoverished Latinos when a CHW is fully integrated within the healthcare management team. The study has several design and community-based methodological strengths. The 12-month-long intervention was followed by a 6-month postintervention maintenance period, allowing us to document the sustainability of the impact. All intervention procedures and data collection occurred in the participants' homes. Although the nature of the intervention did not lend itself to total concealment, the data were collected by highly trained community interviewers (one of which also served as the study's community phlebotomist) not involved in the delivery of the CHW intervention, and the individuals conducting laboratory analyses were blinded to group assignment. The findings have strong internal validity because the RCT achieved remarkable between-group baseline balance. The strong community- and clinic-based supervisory system assured strong intervention fidelity that relied on having only two highly trained CHWs who provided consistent information to participants (Supplementary Data).

The present findings of an HbA_{1c} reduction among the CHW group, ranging from -0.93% [-10.3 mmol/mol] at 3

Table 2-Health insurance, food assistance, social protection, and baseline biomedical factors among Connecticut Latinos with T2D participating in the DIALBEST trial

Variable	All (N = 211)	Control (n = 106)	CHW (n = 105)	P value
Health insurance, food assistance,				
and social protection				
Medicare	33.7	34.0	33.3	0.924
Medicaid	84.1	80.0	88.3	0.099
Supplemental security income	68.9	69.8	68.0	0.773
SNAP	73.3	69.8	76.9	0.244
Systolic blood pressure (mmHg)	118 ± 0.48	116 ± 0.65	119 ± 0.70	0.001
Fasting HbA _{1c} , plasma glucose, and lipid concentrations				
HbA _{1c} (%)	9.58 ± 0.12	9.58 ± 0.17	9.57 ± 0.18	0.981
HbA _{1c} (mmol/mol)	81.2 ± 1.36	81.2 ± 1.91	81.1 ± 1.94	0.981
Glucose (mmol/L)	10.57 ± 0.32	10.48 ± 0.48	10.67 ± 0.44	0.765
Triglycerides (mmol/L)	1.75 ± 0.08	1.69 ± 0.10	1.81 ± 0.12	0.487
Total cholesterol (mmol/L)	4.65 ± 0.08	4.60 ± 0.11	4.69 ± 0.11	0.578
HDL (mmol/L)	1.33 ± 0.02	1.37 ± 0.02	1.29 ± 0.04	0.145
LDL (mmol/L)	2.55 ± 0.07	2.49 ± 0.09	2.61 ± 0.10	0.382
Anthropometry				
Waist circumference (cm)	107.16 ± 1.11	105.85 ± 1.44	108.49 ± 1.70	0.237
Weight (kg)	85.07 ± 1.59	83.34 ± 1.87	86.82 ± 2.57	0.275
Height (cm)	158.48 ± 0.61	158.22 ± 0.85	158.75 ± 0.88	0.669
BMI (kg/m ²)	33.74 ± 0.53	33.38 ± 0.74	34.10 ± 0.77	0.498

Data are % or mean ± SE. SNAP, Supplemental Nutrition Assistance Program.

months to -0.85% [-9.3 mmol/mol] at 12 months followed by sustaining the effect size during the 6-month maintenance period, strongly suggest a clinical (9) and public health (40) impact of DIALBEST. The size of the HbA_{1c} reduction observed in our intervention group at 6 months post enrollment of -0.9%[-9.8 mmol/mol] is fully consistent with the one documented by Spencer et al. (24) of -0.8% [-8.7 mol/mol] at the same time point in their RCT targeting African Americans and Latinos (predominantly Mexican Americans) with T2D living in Detroit predominantly through group sessions (vs. individual home visits as in the present study). In that study, the CHW intervention comprised 11 2-hlong comprehensive diabetes education group sessions offered every other week at community agencies, 2 60-min-long home visits, and 1 clinic visit with a healthcare provider. The study by Rothschild et al. (26) documented among Mexican Americans that 36 CHW home sessions delivered over 2 years led to a net HbA_{1c} reduction of -0.69% [-7.5 mmol/mol] compared with a net reduction of -0.55%[-6.01 mmol/mol] at 18 months postenrollment in our study. Thus, DIALBEST was found to have a similarly strong glycemic control benefit compared with a stand-alone group-based and a more intensive home-based model. However, their study design differed from DIALBEST because it did not integrate CHWs as part of the healthcare management team, the control arm was a newsletter (vs. usual healthcare in DIALBEST), and the study did not assess the sustainability of impact once the intervention ended, included twice as many CHW home visits, and the intervention lasted twice as long. In addition, participants in the Rothschild et al. study had better blood glucose control compared with DIALBEST participants, with \sim 30% of their participants having a baseline $HbA_{1c} < 7\%$ (53 mmol/mol) (vs. 5.2% of DIALBEST participants), and they targeted Mexican Americans (vs. Puerto Ricans/Dominicans in DIALBEST). Thus, DIALBEST adds significant new knowledge from both the perspective of community-based healthcare delivery of T2D self-management and the impact of CHWs on blood glucose control among a highly impoverished population with very poor blood glycemic control. DIALBEST represents the testing of a communitybased real-world healthcare model that can be replicated elsewhere and that is closely aligned with the priorities of the Affordable Care Act.

The more-advanced formal education of the present study's CHWs contrasts with the lower levels of formal education of CHWs used in the study by Rothschild et al. (26). Thus, it is likely that CHWs with lower levels of education than those in DIALBEST can also improve T2D selfmanagement.

Study Limitations

The main study design limitation is that because provider-level data were not collected, it is not possible to disentangle the CHW- and provider-driven pathways that may have led to the significant impact of DIALBEST on improved glycemic control. On the one hand, it is possible that the T2D self-management education provided by the CHWs led to this outcome. On the other hand, because CHWs were integrated as part of the healthcare management team, it is possible that healthcare providers adjusted the treatment of patients accordingly. We speculate that it is likely that both pathways played a role in the observed results, although this hypothesis would need to be tested through further research. Control group participants did not receive the CHW intervention but were also visited at home for data collection, including HbA_{1c} assessment. This may explain why HbA_{1c} also declined in this group, biasing findings toward the null hypothesis.

Conclusion

DIALBEST is a successfully implemented culturally and health literacy-appropriate

Table 3—LME models of intervention on primary and secondary outcomes among Connecticut Latinos with T2D participating in the DIALBEST trial

Outcome	Control	CHW	Group! difference	P valu
rimary outcome				
HbA _{1c} (%)@	9.36 (8.96, 9.75)	8.85 (8.41, 9.28)	-0.51 (-0.83, -0.19)	0.002
HbA _{1c} (mmol/mol)	78.8 (74.4, 83.1)	73.2 (68.4, 78.0)	-5.57 (-9.11, -2.03)	0.002
HbA _{1c} (%)@@				0.002
Baseline	9.76 (9.35, 10.2)	9.70 (9.30, 10.1)	-0.06 (-0.44, 0.33)	0.780
3 months	9.19 (8.71, 9.67)	8.77 (8.34, 9.17)	-0.42 (-0.83, -0.01)	0.043
6 months	9.28 (8.90, 9.66)	8.81 (8.37, 9.26)	-0.47 (-0.93, 0.0001	0.050
12 months	9.42 (9.07, 9.77)	8.85 (8.47, 9.23)	-0.57 (-1.04, -0.09)	0.02
18 months	9.32 (8.91, 9.74)	8.77 (8.35, 9.20)	-0.55 (-0.96 , -0.14)	0.009
HbA _{1c} (mmol/mol)@@	3.02 (8.32, 3.7.1,	0.77 (0.00), 5.120,	0.00 (0.00, 0.1.,	0.002
Baseline	83.2 (78.7, 87.6)	82.6 (78.1, 87.0)	-0.61 (-4.85, 3.64)	0.780
3 months	76.9 (71.7, 82.2)	72.3 (67.7, 77.0)	-4.62 (-9.09, -0.14)	0.04
6 months	77.9 (73.7, 82.1)	72.8 (67.9, 77.7)	-5.10 (-10.2, -0.002)	0.050
12 months	79.4 (75.6, 83.3)	73.3 (69.1, 77.4)	-6.18 (-11.4, -0.96)	0.03
	· · · · · · · · · · · · · · · · · · ·		, , , , , , , , , , , , , , , , , , , ,	
18 months	78.4 (73.9, 83.0)	72.4 (67.7, 77.0)	-6.01 (-10.5, -1.50)	0.009
HbA _{1c} percent change (%)*	-0.96 (-4.96, 3.04)	-6.48 (-11.0, -1.99)	-5.52 (-8.93, -2.11)	0.00
HbA _{1c} percent change (mmol/mol)*	-0.68 (-5.89, 4.53)	-8.01 (-13.9, -2.13)	-7.33 (-11.9, -2.81)	0.00
HbA _{1c} percent change (%)**				0.002
3 months	-2.26 (-7.69, 3.17)	-6.90 (-11.9 , -1.93)	-4.64 (-9.17, -0.11)	0.04
6 months	-1.48 (-6.00, 3.03)	-6.40 (-11.6 , -1.24)	-4.92 (-10.0, 0.19)	0.059
12 months	0.16 (-3.75, 4.08)	-6.02 (-10.4 , -1.63)	-6.19 (-11.1, -1.24)	0.01
18 months	-0.39 (-5.17, 4.38)	-6.76 (-11.8 , -1.72)	-6.37 (-11.1, -1.64)	0.009
HbA _{1c} percent change (mmol/mol)**				0.002
3 months	-2.45 (-9.51, 4.61)	-8.55(-15.1, -2.04)	-6.10 (-12.1, -0.12)	0.04
6 months	-1.44(-7.35, 4.48)	-7.90(-14.7, -1.09)	-6.47(-13.2, 0.26)	0.05
12 months	0.81 (-4.32, 5.94)	-7.45(-13.2, -1.70)	-8.26(-14.7, -1.82)	0.01
18 months	0.19 (-6.04, 6.41)	-8.35 (-15.0, -1.74)	-8.54 (-14.8, -2.26)	0.00
econdary outcomes	, , , , , , , , , , , , , , , , , , , ,	, ,	,	
Glucose (mmol/L)#	11.3 (10.4, 12.3)	10.3 (9.26, 11.3)	-1.08 (-1.78, -0.39)	0.00
Glucose (mmol/L)##	, , , , ,	, , , , , ,	, , , , , , , , , , , , , , , , , , , ,	0.002
Baseline	11.3 (10.4, 12.3)	11.3 (10.3, 12.2)	-0.06 (-1.05, 0.94)	0.91
3 months	10.9 (9.64, 12.1)	10.1 (9.12, 11.2)	-0.75 (-1.84, 0.34)	0.17
6 months	10.7 (9.74, 11.7)	10.3 (9.37, 11.3)	-0.43 (-1.50, 0.65)	0.43
12 months		, , ,	-1.38 (-2.52, -0.25)	
	11.6 (10.7, 12.5)	10.2 (9.07, 11.4)		0.01
18 months	11.7 (10.8, 12.6)	9.92 (8.75, 11.1)	-1.79 (-2.94, -0.64)	0.00
Triglycerides (mmol/L)\$	1.65 (1.53, 1.79)	1.59 (1.47, 1.73)	-0.05 (-0.23, 0.13)	0.549
Triglycerides (mmol/L)\$\$	/)	/>		0.523
Baseline	1.68 (1.53, 1.85)	1.73 (1.57, 1.90)	0.05 (-0.18, 0.27)	
3 months	1.59 (1.41, 1.77)	1.63 (1.46, 1.81)	0.04 (-0.23, 0.31)	
6 months	1.68 (1.51, 1.86)	1.53 (1.36, 1.69)	-0.16 (-0.40 , 0.08)	
12 months	1.66 (1.46, 1.86)	1.56 (1.37, 1.75)	-0.11 (-0.40 , 0.19)	
18 months	1.74 (1.55, 1.93)	1.67 (1.49, 1.86)	-0.06 (-0.36, 0.24)	
Total cholesterol (mmol/L)%	4.51 (4.38, 4.64)	4.56 (4.40, 4.71)	-0.05 (-0.17, 0.28)	0.62
Total cholesterol (mmol/L)%%				0.865
Baseline	4.60 (4.40, 4.79)	4.61 (4.43, 4.82)	0.01 (-0.26, 0.28)	
3 months	4.48 (4.30, 4.69)	4.53 (4.35, 4.74)	0.04 (-0.24, 0.32)	
6 months	4.62 (4.40, 4.82)	4.62 (4.43, 4.82)	-0.00 (-0.28, 0.29)	
12 months	4.53 (4.33, 4.71)	4.62 (4.43, 4.82)	0.09 (-0.20, 0.38)	
18 months	4.55 (4.33, 4.71)	4.49 (4.20, 4.79)	-0.06 (-0.48, 0.36)	
HDL cholesterol (mmol/L)^	1.39 (1.34, 1.44)	1.40 (1.36, 1.45)	0.01 (-0.05, 0.08)	0.72
HDL cholesterol (mmol/L)^^	1.55 (1.54, 1.44)	1.40 (1.50, 1.45)	0.01 (0.03, 0.08)	0.72
` ',	1 25 /1 20 1 /1)	1 22 /1 27 1 20\	-0.03 (-0.10, 0.06)	0.564
Baseline	1.35 (1.30, 1.41)	1.33 (1.27, 1.39)	-0.02 (-0.10, 0.06)	
3 months	1.33 (1.28, 1.39)	1.39 (1.31, 1.45)	0.05 (-0.05, 0.14)	
6 months	1.39 (1.31, 1.47)	1.36 (1.30, 1.43)	0.03 (-0.12, 0.07)	
12 months	1.39 (1.32, 1.46)	1.47 (1.40, 1.53)	0.08 (-0.02, 0.18)	
18 months	1.40 (1.34, 1.47)	1.40 (1.33, 1.47)	-0.003 (-0.08, 0.08)	
LDL cholesterol (mmol/L)&	2.39 (2.26, 2.52)	2.45 (2.30, 2.62)	0.06 (-0.15, 0.27)	0.56
LDL cholesterol (mmol/L)&&				0.598
, ,	2 20 (2 24 2 60)	2.58 (2.40, 2.75)	0.06 (-0.19, 0.32)	
Baseline	2.39 (2.34, 2.69)	2.30 (2.40, 2.73)		
, , ,	2.39 (2.34, 2.69) 2.41 (2.23, 2.59)	2.46 (2.26, 2.46)	0.05 (-0.22, 0.31)	
Baseline				

Table 3—Continued					
Outcome	Control	CHW	Group! difference	P value	
18 months	2.38 (2.17, 2.59)	2.36 (2.10, 2.62)	-0.02 (-0.43, 0.40)		
Weight (kg)+	86.1 (83.7, 88.4)	86.0 (83.3, 88.7)	-0.07 (-3.34, 3.19)	0.964	
Weight (kg)++				0.964~	
Baseline	84.8 (82.2, 87.5)	85.3 (82.7, 87.9)	0.49 (-3.24, 4.21)		
3 months	86.9 (83.4, 90.3)	85.3 (82.1, 88.4)	-1.62 (-6.69, 3.44)		
6 months	85.9 (82.9, 88.9)	85.3 (82.1, 88.5)	-0.60 (-5.03, 3.83)		
12 months	86.4 (82.3, 90.5)	87.3 (84.0, 90.6)	0.90 (-3.31, 5.11)		
18 months	85.4 (82.5, 88.2)	85.9 (81.6, 90.3)	0.54 (-5.70, 6.78)		
Systolic blood pressure (mmHg)=	116 (115, 118)	118 (116, 120)	1.71 (-1.45, 4.86)	0.279	
Systolic blood pressure (mmHg)==				0.313~	
Baseline	119 (116, 121)	120 (117, 123)	1.50 (-2.40, 5.39)		
3 months	115 (112, 117)	117 (114, 119)	2.09 (-1.74, 5.92)		
6 months	118 (114, 121)	117 (113, 120)	-1.02 (-7.11, 5.08)		
12 months	118 (114, 121)	119 (117, 122)	1.20 (-2.70, 5.11)		
18 months	116 (113, 119)	119 (116, 122)	2.87 (-1.74, 7.47)		

Data are mean (95% CI). !Reference is the control group. $^{@}$ Models of HbA $_{1c}$ % and HbA $_{1c}$ change gave identical results. Models included group, time, baseline HbA $_{1c}$ level, age, and antidiabetic medications. $^{@}$ @Models of HbA $_{1c}$ % and HbA $_{1c}$ change gave identical group mean difference results. $Models\ included\ group, time, group-by-time\ interaction,\ baseline\ HbA_{1c}\ level,\ age,\ and\ antidiabetic\ medications.\ {\it ``Overall\ effect\ P'\ values\ for\ properties of the proper$ time point comparisons not reported if P > 0.05. *Model included group, time, baseline HbA_{1c} level, age, and antidiabetic medications. **Model included group, time, group-by-time interaction, baseline HbA_{1c} level, age, and antidiabetic medications. #Model included group, time, baseline glucose level, age, and antidiabetic medications. ##Model included group, time, group-by-time interaction, baseline glucose level, age, and antidiabetic medications. \$Model included group, time, baseline triglyceride level, glucose level, and total cholesterol level. \$\$Model included group, time, group-by-time interaction, baseline triglyceride level, glucose level, and total cholesterol level. %Model included group, time, baseline total cholesterol level, triglyceride level, and anticholesterol medications. %%Model included group, time, group-by-time interaction, baseline total cholesterol level, triglyceride level, and anticholesterol medications. ^Model included baseline HDL level and triglyceride level. ^^Model included group, time, group-by-time interaction, baseline HDL level, and triglyceride level. & Model included group, time, baseline LDL level, triglyceride level, and anticholesterol medications. &&Model included group, time, group-by-time interaction, baseline LDL level, triglyceride level, and anticholesterol medications. +Model included group, time, and baseline weight. ++Model included group, time, group-by-time interaction, and baseline weight. = Model included group, time, baseline systolic blood pressure, total cholesterol level, and antihypertension medications. == Model included group, time, group-by-time interaction, baseline systolic hypertension, total cholesterol level, and antihypertension medications.

intervention that took into account language preferences and socioeconomic circumstances while tailoring the intervention to individual participants. CHWs proved to be essential not only for delivering education on topics directly relevant to T2D self-management but also for providing care coordination and social support services to patients. Thus, CHWs filled huge vacuums of needs that are currently not being addressed by healthcare,




Figure 2—Participant HbA_{1c} percent decline compared with baseline. Net reduction difference in HbA_{1c} between CHW and control groups at 3, 6, 12, and 18 months were -0.42% (P = 0.043), -0.47% (P = 0.050), -0.57% (P = 0.021), and -0.55% (P = 0.009), respectively. Mean differences and P values are from adjusted LMEs.

public care, and social assistance systems surrounding the target community. The Affordable Care Act may represent an opportunity to formalize the role of CHWs as part of T2D healthcare management teams. CHW models should take into account needed service intensity of highly impoverished populations.

Acknowledgments. The authors thank all the study participants and CHWs at the Hispanic Health Council, Hartford, CT.

Funding. DIALBEST was funded by the NIH Minority Health and Health Disparities Institute (grant number P20-MD-001765 to R.P.-E., principal investigator), R.P.-E. received funding support for this publication from the Yale Center for Clinical Investigation through Clinical and Translation Science Award grant UL1-TR-000142 from the National Center for Advancing Translational Sciences, a component of NIH.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center on Minority Health and Health Disparities or the National Institutes of Health (NIH).

Duality of Interest. No potential conflicts of interest relevant to this article were reported. Author Contributions. R.P.-E. was the principal investigator for the study, contributed to the study concept and design, wrote the first draft of the manuscript and subsequent revisions, supervised the trial, and contributed to the data

analyses, G.D. contributed to the study concept and design, conducted the trial, and reviewed drafts of the manuscript, J.C. contributed to the study concept and design and conduct of the study, was Hartford Hospital's senior study coordinator, and reviewed drafts of the manuscript. M.L.F. contributed to the study design, was the study's biomarkers senior scientist, and reviewed drafts of the manuscript, S.S.-P. was the Hispanic Health Council's senior study coordinator; contributed to the study concept, conduct of the study, coordination of the trial. and data quality control; and reviewed drafts of the manuscript. S.V.-L. was a senior study coordinator responsible for fieldwork oversight, intervention fidelity, and data quality checks and reviewed drafts of the manuscript. G.K.-S. contributed to the statistical analyses, managed the study database, conducted laboratory analyses of biomarkers, and reviewed drafts of the manuscript. M.C. conducted laboratory analyses of biomarkers and reviewed drafts of the manuscript, F.M.S. contributed to the statistical analyses framework and reviewed drafts of the manuscript. D.D. was the study's medical director, contributed to the intervention design, and reviewed drafts of the manuscript. R.P.-E. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Prior Presentation. Parts of this study were presented in abstract form at the Experimental Biology Annual Meeting, New Orleans, LA, 18-22 April 2009, and the 70th Scientific Sessions of the American Diabetes Association, Orlando, FL, 25-29 June 2010.

References

- 1. Brown A, Lopez MH. Mapping the Latino population, by state, county and city [article online], 2013. Available from http://www.pewhispanic.org/files/2013/08/latino_populations_in_the_states_counties_and_cities_FINAL.pdf. Accessed 6 July 2014
- 2. Selvin E, Parrinello CM, Sacks DB, Coresh J. Trends in prevalence and control of diabetes in the United States, 1988-1994 and 1999-2010. Ann Intern Med 2014;160:517–525
- 3. Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2010. Natl Vital Stat Rep 2013;61:1–117 4. Lanting LC, Joung IMA, Mackenbach JP, Lamberts SWJ, Bootsma AH. Ethnic differences in mortality, end-stage complications, and quality of care among diabetic patients: a review. Diabetes Care 2005:28:2280–2288
- 5. Pérez-Escamilla R, Garcia J, Song D. Health care access among Hispanic immigrants: ¿alguien esta escuchando? [Is anybody listening?] NAPA Bull 2010;34:47–67
- 6. Perez-Escamilla R. Health care access among Latinos: implications for social and health care reforms. J Hisp High Educ 2010;9:43–60
- 7. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:491–497
- 8. Pleis JR, Ward BW, Lucas JW. Summary health statistics for U.S. adults: National Health Interview Survey, 2009. Vital Health Stat 10 2010:10:1–207
- 9. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–865
- 10. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103–117 11. American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care 2014;37(Suppl. 1):S14–S80
- 12. Lipton RB, Losey LM, Giachello A, Mendez J, Girotti MH. Attitudes and issues in treating Latino patients with type 2 diabetes: views of healthcare providers. Diabetes Educ 1998;24: 67–71
- 13. Adams CR. Lessons learned from urban Latinas with type 2 diabetes mellitus. J Transcult Nurs 2003;14:255–265
- 14. Flores G. Culture and the patient-physician relationship: achieving cultural competency in health care. J Pediatr 2000;136:14–23
- 15. Deitrick LM, Paxton HD, Rivera A, et al. Understanding the role of the promotora in a

- Latino diabetes education program. Qual Health Res 2010;20:386–399
- 16. Brown SA, Hanis CL. Lessons learned from 20 years of diabetes self-management research with Mexican Americans in Starr County, Texas. Diabetes Educ. 2014;40:476–487
- 17. Brown SA, Hanis CL. A community-based, culturally sensitive education and group-support intervention for Mexican Americans with NIDDM: a pilot study of efficacy. Diabetes Educ 1995;21: 203–210
- 18. Osborn CY, Amico KR, Cruz N, et al. A brief culturally tailored intervention for Puerto Ricans with type 2 diabetes. Health Educ Behav 2010;37:849–862
- 19. Two Feathers J, Kieffer EC, Palmisano G, et al. Racial and Ethnic Approaches to Community Health (REACH) Detroit partnership: improving diabetes-related outcomes among African American and Latino adults. Am J Public Health 2005;95:1552–1560
- 20. Lorig K, Ritter PL, Villa F, Piette JD. Spanish diabetes self-management with and without automated telephone reinforcement: two randomized trials. Diabetes Care 2008;31:408–414 21. Lorig K, Ritter PL, Villa FJ, Armas J. Community-based peer-led diabetes self-management: a randomized trial. Diabetes Educ 2009;35: 641–651
- 22. Lujan J, Ostwald SK, Ortiz M. Promotora diabetes intervention for Mexican Americans. Diabetes Educ 2007;33:660–670
- 23. Philis-Tsimikas A, Fortmann A, Lleva-Ocana L, Walker C, Gallo LC. Peer-led diabetes education programs in high-risk Mexican Americans improve glycemic control compared with standard approaches: a Project Dulce promotora randomized trial. Diabetes Care 2011;34:1926–1931
- 24. Spencer MS, Rosland AM, Kieffer EC, et al. Effectiveness of a community health worker intervention among African American and Latino adults with type 2 diabetes: a randomized controlled trial. Am J Public Health 2011;101:2253–2260
- 25. Keyserling TC, Samuel-Hodge CD, Ammerman AS, et al. A randomized trial of an intervention to improve self-care behaviors of African-American women with type 2 diabetes: impact on physical activity. Diabetes Care 2002;25: 1576–1583
- 26. Rothschild SK, Martin MA, Swider SM, et al. Mexican American trial of community health workers: a randomized controlled trial of a community health worker intervention for Mexican Americans with type 2 diabetes mellitus. Am J Public Health 2013;104:1540–1548
- 27. Fitzgerald N, Damio G, Segura-Pérez S, Pérez-Escamilla R. Nutrition knowledge, food label use, and food intake patterns among Latinas with and without type 2 diabetes. J Am Diet Assoc 2008;108:960–967

- 28. Fitzgerald N, Hromi-Fiedler A, Segura-Pérez S, Pérez-Escamilla R. Food insecurity is related to increased risk of type 2 diabetes among Latinas. Ethn Dis 2011;21:328–334
- 29. Bantle JP, Wylie-Rosett J, Albright AL, et al.; American Diabetes Association. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2008;31(Suppl. 1): S61–S78
- 30. Pérez-Escamilla R, Putnik P. The role of acculturation in nutrition, lifestyle, and incidence of type 2 diabetes among Latinos. J Nutr 2007; 137:860–870
- 31. Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A. Improving chronic illness care: translating evidence into action. Health Aff (Millwood) 2001;20:64–78
- 32. Kollannoor-Samuel G, Vega-López S, Chhabra J, Segura-Pérez S, Damio G, Pérez-Escamilla R. Food insecurity and low self-efficacy are associated with health care access barriers among Puerto-Ricans with type 2 diabetes. J Immigr Minor Health 2012;14:552–562
- 33. Kollannoor-Samuel G, Wagner J, Damio G, et al. Social support modifies the association between household food insecurity and depression among Latinos with uncontrolled type 2 diabetes. J Immigr Minor Health 2011;13:982–989
- 34. Kollannoor-Samuel G, Chhabra J, Fernandez ML, et al. Determinants of fasting plasma glucose and glycosylated hemoglobin among low income Latinos with poorly controlled type 2 diabetes. J Immigr Minor Health 2011;13:809–817
- 35. Cruz R. *Process Evaluation of the Diabetes Among Latinos Best Practices Trial (DIALBEST)*. Storrs, CT: University of Connecticut, 2010
- 36. Cruz R, Segura S, Damio G, Perez-Escamilla R. The DIALBEST type 2 diabetes peer counseling intervention: process evaluation (Abstract). FASEB J 2010;24:741.8
- 37. Pérez-Escamilla R. Acculturation, nutrition, and health disparities in Latinos. Am J Clin Nutr 2011:93:1163S–1167S
- 38. Cruz RC, Segura-Perez S, Vega-Lopez S, Chhabra J, Damio G, Perez-Escamilla R. Type 2 diabetes peer counseling intervention improves knowledge and self-management skills (Abstract). FASEB J 2009;23:736.8
- 39. van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res 2007;16: 219–242
- Davidson JA. Treatment of the patient with diabetes: importance of maintaining target HbA (1c) levels. Curr Med Res Opin 2004;20:1919– 1927